TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03354923

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PEERS intervention
Description: PEERS is a 14-week manualized social skills treatment program that targets the friendship skills of adolescents with ASD. In the Israeli adaptation of PEERS, two meeting were extended. An adolescents group will be held concurrently with the parents group in different rooms. Both groups will begin the session with homework review, followed by a didactic social skills lesson, utilizing the teaching methods of modeling and role-playing. In order to practice the newly learned social skills,a behavioral rehearsal interaction will be assigned in the adolescents group. Finally,Socialization homework assignments designed to address further mastery and generalization of newly learned skills within the natural social environment will be assigned too.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS intervention
Description: PEERS is a 14-week manualized social skills treatment program that targets the friendship skills of adolescents with ASD. In the Israeli adaptation of PEERS, two meeting were extended. An adolescents group will be held concurrently with the parents group in different rooms. Both groups will begin the session with homework review, followed by a didactic social skills lesson, utilizing the teaching methods of modeling and role-playing. In order to practice the newly learned social skills,a behavioral rehearsal interaction will be assigned in the adolescents group. Finally,Socialization homework assignments designed to address further mastery and generalization of newly learned skills within the natural social environment will be assigned too.
Study: NCT03901222

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: 20 minutes of anodal tDCS (C3 \& C4/FPZ) 2mA or sham

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: 20 minutes of anodal tDCS (C3 \& C4/FPZ) 2mA or sham
Study: NCT03409497

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concord Grape Juice
Description: Concord Grape Juice

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low flavonoid low essence beverage
Description: Low flavonoid low essence beverage

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low flavonoid beverage
Description: Low flavonoid beverage
Study: NCT00675701

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lixivaptan
Description: capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: tablets
Study: NCT01219088

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Bupivacaine, morphine
Description: 1.8-2.5 mL of 0.5% heavy bupivacaine for spinal anesthesia 20 mL of 0.25% bupivacaine for femoral nerve block 0.1 mg of intrathecal morphine 20 mL of 0.25% bupivacaine for periarticular infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, morphine
Description: 1.8-2.5 mL of 0.5% heavy bupivacaine for spinal anesthesia 20 mL of 0.25% bupivacaine for femoral nerve block 0.1 mg of intrathecal morphine 20 mL of 0.25% bupivacaine for periarticular infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, morphine
Description: 1.8-2.5 mL of 0.5% heavy bupivacaine for spinal anesthesia 20 mL of 0.25% bupivacaine for femoral nerve block 0.1 mg of intrathecal morphine 20 mL of 0.25% bupivacaine for periarticular infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, morphine
Description: 1.8-2.5 mL of 0.5% heavy bupivacaine for spinal anesthesia 20 mL of 0.25% bupivacaine for femoral nerve block 0.1 mg of intrathecal morphine 20 mL of 0.25% bupivacaine for periarticular infiltration
Study: NCT02648399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery：BCND（bilateral central lymph node dissection）

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: surgery：UCND（unilateral central lymph node dissection）
Study: NCT03367273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject
Study: NCT00118573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVAR (Endovascular repair of Abdominal Aortic aneurysm)
Description: AAA repair with endografting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surveillance
Description: Surveillance of AAA without any repair until AAA will reach 5.5cm, become tender or rapidly grow
Study: NCT01155635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Use of Carvedilol with any dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Carvedilol
Description: No use of Carvedilol
Study: NCT03734588

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SPK-8016
Description: adeno-associated viral vector
Study: NCT02980562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycols
Description: (Split dose 2L PEG-Asc)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl
Description: (1L PEG-Asc plus bisacodyl)
Study: NCT04006691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-101 instillations
Description: Treatment with UGN-101 once weekly for a total of 3-6 times; in a retrograde fashion.
Study: NCT06111560

Intervention type: OTHER
Intervention: We do not have any interventions. This study is based on obseravation.
Description: observational retrospective study without any interventions

Intervention type: OTHER
Intervention: We do not have any interventions. This study is based on obseravation.
Description: observational retrospective study without any interventions
Study: NCT00884663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Candesartan cilexitil tablets, 16 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: Propranolol hydrochloride capsules 160 mg once daily, slow release formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets and capsules
Study: NCT02582801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Alfatide Ⅱ PET/CT
Description: Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Alfatide Ⅱ PET/CT
Description: Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
Study: NCT02215239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace intervention
Description: WHO Healthy Workplace Framework and Model. The intervention plan is to implement a cyclic or iterative process recommended by WHO. The process includes eight steps: (1) Mobilize; (2) Assemble; (3) Assess; (4) Prioritize; (5) Plan; (6) Do; (7) Evaluate; (8) Improve. We focus on different phases of exercise and prescribe individualized physical activity program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace intervention
Description: WHO Healthy Workplace Framework and Model. The intervention plan is to implement a cyclic or iterative process recommended by WHO. The process includes eight steps: (1) Mobilize; (2) Assemble; (3) Assess; (4) Prioritize; (5) Plan; (6) Do; (7) Evaluate; (8) Improve. We focus on different phases of exercise and prescribe individualized physical activity program.
Study: NCT01030276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: Bright light therapy
Study: NCT01608919

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: blood tests
Description: thromboelastogram platelet mapping
Study: NCT03133455

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.
Description: Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.
Study: NCT01084408

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SeQuent®Please (Paclitaxel coated balloon)
Description: PCI of de-novo lesions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus™Liberté™ (Paclitaxel eluting stent)
Description: PCI of de-novo lesions
Study: NCT02792296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project: EVO Monitor
Description: Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
Study: NCT01030276

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactive placebo-light
Description: In this arm, patients will not get any bright-light therapy in a double-blind setting
Study: NCT01051973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: A 10-week treatment based on exposure to symptoms and related feelings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management
Description: A 10-week stress management treatment including applied relaxation and dietary advice.
Study: NCT05467865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZELIAKIDE
Description: The nutrition education program will be adapted to the curriculum of the schools. The intervention will consist of 8 sessions and the main topics will be: (1) to understand the balanced diet and to apply it to one´s own diet, (2) to learn what celiac disease and gluten are, (3) to promote social inclusion.~Each session will last 60 minutes and they will take place during school hours. The whole intervention will last 4 weeks, 2 sessions per week. Teaching-learning process will be developed through games and experiments.~Designed activities are based on IBL methodology, which has proven to be very effective in science teaching-learning processes. As a result, inquiry-oriented TLS has been developed, focused on facilitating children's understanding of the research process.
Study: NCT00669136

Intervention type: DRUG
Group type: OTHER
Intervention: AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
Description: AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
Study: NCT00245427

Intervention type: DRUG
Group type: OTHER
Intervention: all macrolide antibiotics
Description: Varies based on antibiotic

Intervention type: DRUG
Group type: OTHER
Intervention: all beta-lactam antibiotics
Description: Varies based on antibiotic
Study: NCT01629134

Intervention type: DEVICE
Intervention: Crosslinked hyaluronic acid gel
Description: All treatments are carried out according to the physician's experience and the Directions for Use
Study: NCT01227096

Intervention type: DEVICE
Intervention: Electrical acupuncture stimulation
Description: electroacupuncture would be administered on the bilateral P6 acupoint after anesthesia induction, but prior to surgery.
Study: NCT03606239

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: isotoxic hypofractionated group
Description: the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0\> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible，and the same time use the Platinum-containing drugs: docetaxel + lobaplatin Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1, repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.Consolidate chemotherapy up to 4 cycles after radiotherapy, as above.
Study: NCT02913469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: The patients in group A would be administrated intravenous morphine 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: The patients in group A would be administrated intravenous morphine 5mg

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: metoclopramide
Description: the patients in group C would be administrated intravenous metoclopramide 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide
Description: the patients in group C would be administrated intravenous metoclopramide 10mg

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: saline
Description: the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.
Study: NCT00393978

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quetiapine and placebo
Description: placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
Study: NCT02792296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project: EVO Monitor
Description: Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Project: EVO Monitor
Description: Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
Study: NCT01702623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine
Study: NCT01524159

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: bromelain capsule
Description: Bromelain group received bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (wheat starch)
Description: Placebo group received placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
Study: NCT00393978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine and Topiramate
Description: topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).
Study: NCT00637052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-520, KSP(Eg5) inhibitor; intravenous
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
Study: NCT02173691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium inhalation powder capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol inhalation aerosol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation aerosol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo inhalation aerosol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation powder capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo inhalation powder capsules
Study: NCT01894386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF 400 mcg
Description: 100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)
Study: NCT01573494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling of blood
Description: 7,5 ml of blood
Study: NCT01894386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF 400 mcg
Description: 100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF 400 mcg
Description: 100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF 400 mcg
Description: 100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 500 mcg
Description: 125 mcg powder for inhalation delivered by DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 500 mcg
Description: 125 mcg powder for inhalation delivered by DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 500 mcg
Description: 125 mcg powder for inhalation delivered by DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 500 mcg
Description: 125 mcg powder for inhalation delivered by DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 250 mcg
Description: 62.5 mcg powder for inhalation delivered by DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 250 mcg
Description: 62.5 mcg powder for inhalation delivered by DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 250 mcg
Description: 62.5 mcg powder for inhalation delivered by DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC 250 mcg
Description: 62.5 mcg powder for inhalation delivered by DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI 100 mcg
Description: 25 mcg powder for inhalation delivered by DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI 100 mcg
Description: 25 mcg powder for inhalation delivered by DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI 100 mcg
Description: 25 mcg powder for inhalation delivered by DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI 100 mcg
Description: 25 mcg powder for inhalation delivered by DPI
Study: NCT03631680

Intervention type: PROCEDURE
Intervention: Bilateral Oophorectomy Surgery
Description: Women undergoing elective, laparoscopic bilateral oophorectomy surgery will be enrolled.
Study: NCT02837731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment Starling SV monitor
Description: A dynamic assessment of fluid responsiveness will be performed at every clinical decision point for the first 72 hours of study enrollment. Fluid responsiveness will be assessed using a passive leg raise (PLR) and Starling SV hemodynamic monitor to guide corresponding treatment.
Study: NCT03351608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Description: For moderate NMB reversal, a single i.v. bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Description: For moderate NMB reversal, a single i.v. bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Description: For deep NMB reversal, a single i.v. bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Description: For deep NMB reversal, a single i.v. bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine + Glycopyrrolate
Description: For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine + Atropine
Description: For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
Study: NCT03778346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T therapy in Relapsed/Refractory multiple myeloma
Description: Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells to treat Relapsed/Refractory multiple myeloma
Study: NCT01017536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402
Description: AERAS-402 is a replication-deficient serotype 35 adenovirus containing DNA that expresses a fusion protein of three Mycobacterium tuberculosis (Mtb) antigens: 85A, 85B and TB10.4.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was the identical buffer solution in which AERAS-402 is formulated.
Study: NCT01186068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V-101
Description: Cream QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V-101
Description: Cream QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V-101
Description: Cream QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V-101
Description: Cream QD
Study: NCT00743119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Description: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Description: Placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inactive marijuana (0% THC)
Description: Inactive marijuana cigarettes (0% THC) provided by NIDA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inactive marijuana (0% THC)
Description: Inactive marijuana cigarettes (0% THC) provided by NIDA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive marijuana (0% THC)
Description: Inactive marijuana cigarettes (0% THC) provided by NIDA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Dronabinol
Description: Dronabinol 10mg
Study: NCT01186068

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vehicle
Description: Cream QD